News

Zacks Investment Research on MSN4h
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...
Novo Nordisk Teams With WeightWatchers to Expand Wegovy Access
Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...
NL Times12h
Nutrition Center advises caution in using Ozempic, Wegovy for weight loss
The Nutrition Center warns people who want to lose weight not to take medication too lightly. “It may seem easy, but do not ...
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.